The approval of therapeutic agents that are tested in patients deemed ineligible for intensive or aggressive therapy is increasingly popular. This approach enables comparisons of novel therapies with less-aggressive agents, as well as data from nonrandomized studies to be used for market authorization. Herein, we discuss three mechanisms that could be adopted to avoid the temptation of applying this strategy excessively.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Cortes, J. E. et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33, 379–389 (2018).
Mateos, M.-V. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N. Engl. J. Med. 378, 518–528 (2018).
DiNardo, C. D. et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 19, 216–228 (2018).
Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017).
U.S. Food and Drug Administration. 2009 meeting materials, Oncologic Drugs Advisory Committee. FDA https://wayback.archive-it.org/7993/20170403224034/https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm126185.htm (updated 24 Feb 2015).
Woyach, J. A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl. J. Med. 379, 2517–2528 (2018).
Tao, D. & Prasad, V. Choice of control group in randomised trials of cancer medicine: are we testing trivialities? Lancet Oncol. 19, 1150–1152 (2018).
Durie, B. G. M. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389, 519–527 (2017).
Acknowledgements
The work of V.P. is funded by the Laura and John Arnold Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.J.C. reports receiving consulting fees from Syros. V.P. receives royalties from his book Ending Medical Reversal, has received honoraria for Grand Rounds or lectures from several universities, medical centres, non-profit groups and professional societies and is a writer for Medscape. J.G. declares no competing interests.
Additional information
Related links
ClinicalTrials.gov: https://clinicaltrials.gov/
Supplementary information
Rights and permissions
About this article
Cite this article
Cook, R.J., Gill, J. & Prasad, V. Registration studies — when should patients be deemed ineligible for aggressive therapy?. Nat Rev Clin Oncol 16, 333–334 (2019). https://doi.org/10.1038/s41571-019-0180-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0180-x